KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Total Liabilities (2019 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Total Liabilities for 5 consecutive years, with $773.7 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Total Liabilities rose 79.53% year-over-year to $773.7 million, compared with a TTM value of $773.7 million through Sep 2023, up 79.53%, and an annual FY2022 reading of $803.0 million, up 59.46% over the prior year.
  • Total Liabilities was $773.7 million for Q3 2023 at Ginkgo Bioworks Holdings, down from $788.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.4 billion in Q2 2021 and bottomed at -$516.3 million in Q3 2020.
  • Average Total Liabilities over 5 years is $528.7 million, with a median of $518.1 million recorded in 2021.
  • The sharpest move saw Total Liabilities skyrocketed 203.16% in 2021, then crashed 68.82% in 2022.
  • Year by year, Total Liabilities stood at -$501.9 million in 2019, then soared by 140.87% to $205.1 million in 2020, then surged by 145.54% to $503.6 million in 2021, then soared by 59.46% to $803.0 million in 2022, then dropped by 3.65% to $773.7 million in 2023.
  • Business Quant data shows Total Liabilities for DNA at $773.7 million in Q3 2023, $788.4 million in Q2 2023, and $809.6 million in Q1 2023.